Development of the Third Generation EGFR Tyrosine Kinase Inhibitors for Anticancer Therapy

Publisher： Bentham Science Publishers

E-ISSN： 1875-533x|23|29|3343-3359

ISSN： 0929-8673

Source： Current Medicinal Chemistry, Vol.23, Iss.29, 2016-10, pp. : 3343-3359

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Rational Design of Potent and Selective EGFR Tyrosine Kinase Inhibitors as Anticancer Agents

By  

Current Cancer Drug Targets, Vol. 1, Iss. 2, 2001-08 ,pp. : 129-140

Bentham Science Publishers

Access to resources Recommend Favorite

Current progress towards the development of tyrosine kinase inhibitors as anticancer agents

By Bridges A.  

Expert Opinion on Emerging Drugs, Vol. 3, Iss. 1, 1998-06 ,pp. : 279-292

Informa Healthcare

Access to resources Recommend Favorite

Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents

By Laird A Douglas   Cherrington Julie M  

Expert Opinion on Investigational Drugs, Vol. 12, Iss. 1, 2003-01 ,pp. : 51-64

Informa Healthcare

Access to resources Recommend Favorite

Development for Anticancer Therapy: Small-Molecule Inhibitors Targeting Protein Kinase B

By  

Mini Reviews in Medicinal Chemistry, Vol. 13, Iss. 9, 2013-01 ,pp. : 1272-1294

Bentham Science Publishers

Access to resources Recommend Favorite

Protein tyrosine kinase inhibitors as anticancer agents

By Supuran Claudiu T   Scozzafava Andrea  

Expert Opinion on Therapeutic Patents, Vol. 14, Iss. 1, 2004-01 ,pp. : 35-53

Informa Healthcare

Access to resources Recommend Favorite